Vascular Cardiologist @umichCVC. #thrombosis, #CVcoag, #ImpSci. Co-director @MAQI_2. Board of Directors @AnticoagForum. Tweets my own. RT≠endorsement. 🏳️🌈
Oct 31 • 22 tweets • 7 min read
In case you missed it, the PEERLESS trial results were presented at #TCT24 yesterday and published in @CircAHA. ahajournals.org/doi/10.1161/CI…
The question being asked in this RCT is which approach to catheter-based acute PE management is superior: large bore mechanical thrombectomy (LBMT) or catheter-based thrombolysis (CDL)?
Aug 30, 2022 • 7 tweets • 3 min read
So much research has been done on management of warfarin before and after procedures. But direct oral anticoagulants are more commonly prescribed. How is bleeding risk similar or different between DOAC- and warfarin-treated patients? 🧵
DOACs have a shorter half-life than warfarin. So they don’t require “bridging” with heparin. Warfarin has a long half-life, so sometimes we give bridging heparin… but that’s becoming less and less common.
Aug 22, 2022 • 8 tweets • 2 min read
Have you seen the newest perioperative #cvCoag guidelines from @accpchest? I've had some time to digest this exciting new document and wanted to share a few take away points. pubmed.ncbi.nlm.nih.gov/35964704/
First big recommendation that might catch folks off guard: For patients with mech valve and VKA use, "we suggest against heparin bridging". Will this be a big change for your practice? How to implement and get buy-in from clinicians & patients?
May 3, 2022 • 12 tweets • 5 min read
Reflections from Day 2 of @ACCinTouch#EmergingFaculty Leadership course. First, what an incredibly talented group of educators who came together to improve their craft! They explicitly asked for feedback, which is rarely given after an educational talk.
We were reminded of several key presenter pearls from Mike Monahan. Including: 1) to fight nerves, remember that the learner is on your side; and 2) address the “What? So What? and Now What?” anytime you are teaching.
